Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Center, Korea
NRG Oncology
Mayo Clinic
Janssen Research & Development, LLC
Aarhus University Hospital
Janssen Research & Development, LLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
UroGen Pharma Ltd.
UroGen Pharma Ltd.
National Cancer Institute (NCI)
Aarhus University Hospital
First Affiliated Hospital of Wenzhou Medical University
Abnoba Gmbh
Hospital Centre Biel/Bienne
Tongji Hospital
Fox Chase Cancer Center
Merck Sharp & Dohme LLC
University of Florida
UroGen Pharma Ltd.
Radiation Therapy Oncology Group
UroGen Pharma Ltd.
Nottingham University Hospitals NHS Trust
UroGen Pharma Ltd.
University of Bern
McMaster University
University of Sydney
Corewell Health West
Mayo Clinic
First Affiliated Hospital Xi'an Jiaotong University
UroGen Pharma Ltd.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Viralytics
Halozyme Therapeutics
CG Oncology, Inc.
UroGen Pharma Ltd.
UroGen Pharma Ltd.
Medical Enterprises Ltd.
Institute of Cancer Research, United Kingdom
Samyang Biopharmaceuticals Corporation
Azienda Ospedaliera "Sant'Andrea"
TC Erciyes University
Bioniche Life Sciences Inc.
UroGen Pharma Ltd.
The University of Texas Health Science Center at San Antonio
Memorial Sloan Kettering Cancer Center
Duke University
National Cancer Institute (NCI)